Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Characterization of NDMM patients treated with daratumumab, lenalidomide, bortezomib and dexamethasone who fail to achieve a VGPR or have early progression
Jonathan L. Kaufman, Efstathios Kastritis, Nisha S. Joseph, Maria Gavriatopoulou, Lilly Gu, Craig C. Hofmeister, Vikas A. Gupta, Evangelos Terpos, Ajay K. Nooka, Sagar Lonial, Meletios A Dimopoulos (2025). Characterization of NDMM patients treated with daratumumab, lenalidomide, bortezomib and dexamethasone who fail to achieve a VGPR or have early progression. , 146(Supplement 1), DOI: https://doi.org/10.1182/blood-2025-407.
Article35 days agoThe clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
Pralay Mukhopadhyay, Hesham Abdullah, Joanna Opalinska, Prani Paka, Eric Richards, Katja Weisel, Suzanne Trudel, María‐Victoria Mateos, Meletios A Dimopoulos, Sagar Lonial (2025). The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development. , 15(1), DOI: https://doi.org/10.1038/s41408-025-01212-0.
Article35 days agoEXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma
Sagar Lonial, Meletios A Dimopoulos, Jesús G. Berdeja, Paul G. Richardson, Hang Quach, Paula Rodríguez‐Otero, Paulo Maciag, Kevin Hong, Michael Amatangelo, Min Chen, Niels W.C.J. van de Donk (2025). EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma. , 21(14), DOI: https://doi.org/10.1080/14796694.2025.2501920.
Article35 days agoDesign of the phase 3 DREAMM-10 study: Belantamab mafodotin plus lenalidomide and dexamethasone (BRd) vs daratumumab plus lenalidomide and dexamethasone (DRd) in transplant-ineligible, newly diagnosed multiple myeloma (TI-NDMM).
Sagar Lonial, Ho‐Young Yhim, Vanesa Caruso, Jae-Cheol Jo, Sung‐Hoon Jung, Youngil Koh, Peter Barth, Samineh Deheshi, Eleftheria Kalaitzaki, Brandon E. Kremer, Julia Boyle, Nicola Jackson, Wei Sun, Fernando Carreno, Pralay Mukhopadhyay, Joanna Opalińska, Meletios A Dimopoulos (2025). Design of the phase 3 DREAMM-10 study: Belantamab mafodotin plus lenalidomide and dexamethasone (BRd) vs daratumumab plus lenalidomide and dexamethasone (DRd) in transplant-ineligible, newly diagnosed multiple myeloma (TI-NDMM).. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.tps7567.
Article35 days agoPractical Guidance on Clinical Management of Belantamab Mafodotin‐Associated Ocular Events
Evangelos Terpos, Suzanne Trudel, María‐Victoria Mateos, Nicolás Alejandre, Kathryn Colby, Meletios A Dimopoulos, Simona Degli Esposti, Asim V. Farooq, Maria Gavriatopoulou, Francesca Gay, Vânia Hungria, K. Martin Kortüm, Xavier Leleu, Sagar Lonial, Hang Quach, Lugui Qiu, Karthik Ramasamy, Kazuhito Suzuki, Katja Weisel, Paul G. Richardson (2025). Practical Guidance on Clinical Management of Belantamab Mafodotin‐Associated Ocular Events. , 100(10), DOI: https://doi.org/10.1002/ajh.70015.
Article35 days ago